Abstract
Plasma concentrations of three major vitamin D3 metabolites, 25-hydroxyvitamin D3 (25-OHD3), 24R, 25-dihydroxyvitamin D3 (24,25-(OH)2D3), and 1 alpha, 25-dihydroxyvitamin D3 (1,25-(OH)2D3), were determined serially in patients with gynecological malignancies treated by chemotherapy which included cisplatin. While 25-OHD3 and 24,25-(OH)2D3 levels did not change regularly, 1,25-(OH)2D3 decreased significantly (50%) after only one or two courses of the treatment in all cases. In concert with declining 1,25-(OH)2D3, the PTH levels increased two or three times. The results were explained by the impairment by cisplatin of mitochondrial function in proximal tubules in the kidney.
MeSH terms
-
24,25-Dihydroxyvitamin D 3 / blood
-
25-Hydroxyvitamin D3 1-alpha-Hydroxylase / metabolism
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Calcifediol / blood
-
Calcitriol / blood
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Cisplatin / pharmacology*
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Epirubicin / administration & dosage
-
Female
-
Genital Neoplasms, Female / blood
-
Genital Neoplasms, Female / drug therapy*
-
Genital Neoplasms, Female / surgery
-
Humans
-
Kidney Diseases / chemically induced
-
Kidney Tubules, Proximal / drug effects*
-
Kidney Tubules, Proximal / metabolism
-
Middle Aged
-
Mitochondria / drug effects*
-
Mitochondria / enzymology
-
Mitomycin / administration & dosage
-
Parathyroid Hormone / blood
-
Vitamin D / metabolism*
Substances
-
Parathyroid Hormone
-
Vitamin D
-
Epirubicin
-
24,25-Dihydroxyvitamin D 3
-
Mitomycin
-
Doxorubicin
-
Cyclophosphamide
-
25-Hydroxyvitamin D3 1-alpha-Hydroxylase
-
Calcitriol
-
Calcifediol
-
Cisplatin